ARTICLE | Clinical News
Comfyde carisbamate: Phase III data
December 15, 2008 8:00 AM UTC
A double-blind, international Phase III trial in 555 patients showed that both 200 and 400 mg/day doses of Comfyde missed the co-primary endpoints of median percent reduction in seizure frequency vs. ...